More recently, CD4 + CD127lowCD25highFOXP3 + Tregs were found to be reduced in MPN patients, compared to healthy subjects, but such a decrease became even more profound upon treatment with JAK2 inhibitors (while, on the other hand, Th17 exhibited a slow expansion) [109]. Here, JAK2 is linked to myeloproliferative disorder.